Compare Crocs, Inc. (CROX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Novo Nordisk A/S — how do they compare? Crocs, Inc. trades at $131.61 (market cap $6.31B), while Novo Nordisk A/S trades at $45.75 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 32.9× Crocs, Inc.'s market cap, and Novo Nordisk A/S pays a 3.81% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals.
| CROX | NVO | |
|---|---|---|
Market Cap | $6.31B | $207.85B |
Sector | Consumer Staples | Health |
52-Week High | $141.19 | $63.98 |
52-Week Low | $73.39 | $35.29 |
Enterprise Value | $7.83B | $222.55B |
Dividend Yield | — | 3.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
